Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Accumulated Depreciation (2021 - 2025)

Historic Accumulated Depreciation for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $4.4 million.

  • Lyra Therapeutics' Accumulated Depreciation rose 9848.28% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 9848.28%. This contributed to the annual value of $4.1 million for FY2024, which is 11494.01% up from last year.
  • Latest data reveals that Lyra Therapeutics reported Accumulated Depreciation of $4.4 million as of Q3 2025, which was up 9848.28% from $4.3 million recorded in Q2 2025.
  • Lyra Therapeutics' Accumulated Depreciation's 5-year high stood at $4.7 million during Q3 2022, with a 5-year trough of $1.9 million in Q4 2023.
  • Its 5-year average for Accumulated Depreciation is $3.6 million, with a median of $4.1 million in 2024.
  • Its Accumulated Depreciation has fluctuated over the past 5 years, first tumbled by 5397.7% in 2023, then skyrocketed by 11494.01% in 2024.
  • Over the past 5 years, Lyra Therapeutics' Accumulated Depreciation (Quarter) stood at $3.9 million in 2021, then increased by 7.61% to $4.2 million in 2022, then crashed by 53.98% to $1.9 million in 2023, then skyrocketed by 114.94% to $4.1 million in 2024, then increased by 7.73% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.3 million for Q2 2025, and $4.3 million during Q1 2025.